Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Almost over almost penny trading season
Merry summer
$LVGI Limitless Venture Group Inc. (OTCBB: LVGI)
$WPWR Well Power, Inc. (WPWR) – Promoting Clean Energy Solutions WPWR
Well Power is seeking to engage the attention of oil and gas producing companies in its operations. To accomplish this, the company is employing a two-pronged approach: (1) it is aiming to educate them about the unique micro-refinery unit it is backing; and (2) it is working on creating partnership opportunities that make these companies allies.
Well Power already has a strong ally in ME Resources (“MEC”), the license holder developing an economical, mobile and scalable Micro-Refinery Unit (the “MRU”) to process raw natural gas into clean power and green fuel (diluents, drop-in diesel and pipeline quality synthetic crude). MEC’s proposed solution works in chorus; it concurrently reduces carbon dioxide (CO2) emissions while creating positive income streams from minimal capital spending.
The MRU has modular configuration flexibilities. The unit is scalable, mobile, cost-effective, energy efficient, high yield, single vessel, skid mounted, custom configured and being primed to turn wasted gas into clean power and engineered fuels (i.e. revenue). According to MEC’s designs, the MRU assembles proven industrial technologies with a proprietary micro-reactor system for hydrocarbon processing and catalytic reactions. A notably novel system, this process is also the key technology component that enables the unit to be easily transported and financially viable.
Designed to process raw natural gas flows of between 75 Mcf to 250 Mcf, the MRU first conditions then converts methane and condensates to Syngas (carbon monoxide and hydrogen). Following this step, a Fischer-Tropsch reaction occurs that produces power from the heat generated by exothermic reactions and combustion as well as green fuel.
In short, once the micro-refinery unit is developed, its advantages would be ample:
• Energy efficient
• High yield (C5+ > 50%)
• Improved safety
• Units > 100 MCFD
• Mobility advantages
$WPWR Well Power, Inc. (WPWR) – Promoting Clean Energy Solutions WPWR
Well Power is seeking to engage the attention of oil and gas producing companies in its operations. To accomplish this, the company is employing a two-pronged approach: (1) it is aiming to educate them about the unique micro-refinery unit it is backing; and (2) it is working on creating partnership opportunities that make these companies allies.
Well Power already has a strong ally in ME Resources (“MEC”), the license holder developing an economical, mobile and scalable Micro-Refinery Unit (the “MRU”) to process raw natural gas into clean power and green fuel (diluents, drop-in diesel and pipeline quality synthetic crude). MEC’s proposed solution works in chorus; it concurrently reduces carbon dioxide (CO2) emissions while creating positive income streams from minimal capital spending.
The MRU has modular configuration flexibilities. The unit is scalable, mobile, cost-effective, energy efficient, high yield, single vessel, skid mounted, custom configured and being primed to turn wasted gas into clean power and engineered fuels (i.e. revenue). According to MEC’s designs, the MRU assembles proven industrial technologies with a proprietary micro-reactor system for hydrocarbon processing and catalytic reactions. A notably novel system, this process is also the key technology component that enables the unit to be easily transported and financially viable.
Designed to process raw natural gas flows of between 75 Mcf to 250 Mcf, the MRU first conditions then converts methane and condensates to Syngas (carbon monoxide and hydrogen). Following this step, a Fischer-Tropsch reaction occurs that produces power from the heat generated by exothermic reactions and combustion as well as green fuel.
In short, once the micro-refinery unit is developed, its advantages would be ample:
• Energy efficient
• High yield (C5+ > 50%)
• Improved safety
• Units > 100 MCFD
• Mobility advantages
Check out $MEDH...
The OS is only 28 million with a 4 million float..
There is no debt and no dilution..
This moves on air..
It's hard to load because it such a low float. I'm still loading.
This is gonna see .30 to .40 cents easy.. Might even see $1.00
Current pps is .0169
$PMCB Pharmacyte Biotech Inc (OTCMKTS:PMCB) Soars, Opens Floodgates For Catalysts
https://www.insiderfinancial.com/pharmacyte-biotech-inc-otcmktspmcb-soars-opens-floodgates-for-catalysts/118471/
$PMCB Technical Buzz on PharmaCyte Biotech, Inc. (OTCPK:PMCB)
http://wslnews.com/technical-buzz-on-pharmacyte-biotech-inc-otcpkpmcb/31920/
$PMCB Colon Cancer Pipeline Market 2016 Review Report Covering Therapeutics Development
http://www.prnewswire.com/news-releases/colon-cancer-pipeline-market-2016-review-report-covering-therapeutics-development-587207931.html
Veni Vidi Vici
Glory to God God Greatly Bless Greatly Prosper Great undervalued Company $ RBNW $
Toggle navigation
Marketwired
SOURCE: Renewable Energy and Power, Inc.
Renewable Energy and Power, Inc.
April 29, 2016 08:45 ET
Renewable Energy and Power, Inc., Opens 2nd Sales and Distribution Center to Service the Northeast USA With LED Lighting, Solar and Wind Power
NORTH LAS VEGAS, NV--(Marketwired - Apr 29, 2016) - Renewable Energy and Power, Inc., (OTC PINK: RBNW), a diversified corporation with markets in energy-saving technologies of both solar and wind energy, and LED lighting, is pleased to announce that the Company has opened its second sales and distribution center to service residential and commercial customers in the Northeast USA region with REAP products.
"This center in Delanco, New Jersey, will cover the Northeast region," said CEO Donald MacIntyre. "In addition to REAP's manager, there are seven sales representatives covering their local states. Additionally, a contractor who employs sixty technicians will handle the installation and maintenance for our customers using REAP's bucket truck for outside area lighting."
The manager of the facility for REAP's GoToGreenlights division (www.gotogreenlights.com) will be Mr. Ray Gunter who has an extensive background in LED lighting and solar power. Located in Delanco, New Jersey, Ray may be contacted at (609) 315-8977, rayg@reappower.com.
Renewable Energy and Power, Inc.'s website, www.reappower.com, illustrates the important services and products Renewable Energy and Power, Inc. (REAP) provides to the Green Energy market to make it competitive with fossil fuels by employing proprietary new technologies in combination with existing solar and wind-power electric generation and LED lighting. REAP functions in both domestic and international markets that are in vigorous growth stages with long-term prospects. Federal and state legislation in the United States, including many tax incentives, are driving businesses and consumers to replace older technologies with the new solar and LED alternatives offered by REAP.
Safe Harbor Act: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
For information:
info@reappower.com
Phn: 702-685-9524
www.reappower.com
Desktop version
View Desktop Version
Pour voir la version complète
,,,,,,,GOD is good he has risen. (LFAP) +113%
,,,,,,,"Happy weekend brothers~~MoneyMade" LFAP NOW
,,,,,,,AMAZING PREDICTION: WHY THE WORLD NEEDS YOU!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119916273
Not gonna lie, some days I do miss the camaraderie and long conversations we use to have for almost two years in the Secret Society, I don't know if that makes me sad or not, but even after traveling the world and meeting hundreds of strangers and making real life friends, being able to talk to total strangers about anything was always comforting.
SuperTrooper A.k.a StockWizard A.k.a TheWizardofPot A.k.a LordoftheTitans
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
THANK YOU MY BROTHER!
NETE gig drop in good earnings. Time to squeeze the chit out if shorts!
GFOX check out the next one about to go beast mode
GOOD EVENING MY FIRST ORDER COMRADES, IT IS I THE LORD OF THE TITANS, ONCE AGAIN I HAVE RETURNED WITH A BARGAIN BUSTING MJ PICK OF THE YEAR!!!
I HAVE BEEN INACTIVE FOR THE MOST PART AS I CONTINUE TO TRAVEL THE WORLD, BUT I HAD TO STOP BY TO GIVE YOU GUYS A SNEAK PEAK AT THIS BAD BOY:
$DEWM
THE TECHNICALS, THE FUNDAMENTALS, THE BUSINESS, THE MJ HYPE, EVERYTHING ABOUT THIS SCREAMS .03+ AS IT DID BACK IN 2014 AND IT IS READY AGAIN!
IT'S TIME TO DUST OFF THOSE PUMP HATS, WE ARE ABOUT TO DO BUSINESS WITH A BEAST!!!
GOOD LUCK TO ALL AND HAPPY EASTER MY FRIENDS!!!
===> ASUV .019. Merger play! 90M AS 74M OS (CEO owns 40%) <===
BETS news!
Seanimac announces record revenues and scores big with merger
Source: InvestorsHub NewsWire
Seanimac announces record revenues and scores big with merger.
SeanieMac Holdings UK merges ApolloBet UK and SeanieMac Ireland
While generating $600,000 in gross revenue last week.
Huntington, NY -- March 23, 2016 -- InvestorsHub NewsWire
SeanieMac Holdings UK (OTC:BETS) officially announced today that it had finalized the acquisition of the business assets of SeanieMac Ireland and ApolloBet UK and consolidated all of the clients (60,000 plus clients of ApolloBet UK and 50,000 SeanieMac Ireland) under one trading platform. Clients of SeanieMac Ireland have been notified of the consolidation which will take place in the next few days depending on regulatory and technical requirements.
Once the clients are trading under a single platform, the Company will be providing financial updates on the consolidated trading and financial projections for 2016.
The Cheltenham Horse Race last week provided a lot of excitement and a very lucrative week with record revenue of over $600,000 USD for the week as a prelude to a great year ahead. The turnover revenue generated by Apollo Bet UK alone, makes the pending combination even more impressive.
Shane ODriscoll, "The substantial redundant costs in running both companies are now eliminated by the consolidation. This strategically calculated decision is expected to accelerate our growth projections in the medium to long-term. Last year the global online gambling market was worth roughly $41.4 billion with the European online gambling market being the largest in the world. We are now positioned to be one of the bigger players. We will provide detailed and multiple updates in the next few weeks on our accomplishments and plans for the year.
Internet gambling is expected to generate revenue exceeding 56 billion dollars in 2018, doubling that of 2009. The company is positioning itself to take full advantage of this growth industry through this merger, one of many planned endeavors this year.
Safe Harbor Statement
This news release contains forward-looking statements that involve risks, uncertainties and assumptions. If such risks or uncertainties materialize or such assumptions prove incorrect, the results of Seaniemac International, Ltd. and its consolidated subsidiaries could differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to statements regarding our expectations regarding amounts staked and gross profits and our marketing initiatives. Such risks and uncertainties include, among other things, the uncertainty regarding consumer preferences, a decline in the popularity of our website and competition in the online gambling industry. Seaniemac assumes no obligation and does not intend to update these forward-looking statements.
A further description of risks and uncertainties can be found in Seaniemac International, Ltd.s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 and in its reports on Form 10-Q and Form 8-K.
Contact Info:
(386) 409-0200
$PMCB All About PMCB
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=119226438
$ISBG Celebrity Artists Shad Moss (Bow Wow) and Yung Joc Join the ISBG Family
INTERNATIONAL SPIRIT & BEVERAGE GROUP, INC. Financials EDGAR Online Financials 1 mth 19 days ago
More
HOUSTON, TX--(Marketwired - Dec 9, 2015) - International Spirit & Beverage Group, Inc. (a Nevada Corporation) (OTC PINK: ISBG) ("ISBG"), an alcoholic beverage company specializing in the development, global sales and marketing of innovative wine & spirits brands, including the award-winning Cavoda Vodka, Besado Tequila, and Dziaq Liqueur, is pleased to announce the signing of Shad Moss (Bow Wow) and Yung Joc.
The individual contracts call for each artist to be responsible for assuming the role of "brand face" for ISBG's Besado Tequila in the urban market. They will help create advertising, content for brand awareness, and include the brand in their songs, videos, and concerts. Social media will be emphasized especially on Twitter and Instagram. Each artist was compensated with 5,000,000 million shares in ISBG stock plus stock and cash incentives upon the achievement of various significant sales milestones of ISBG products.
"I'm excited to be part of the ISBG family," stated Shad Moss (Bow Wow). "I believe ISBG's Besado Tequila will prove to be an up-and-coming winner. As a partner with ISBG I look forward to helping to take this to the next level."
"I am proud to be associated with a premium tequila like Besado," added Yung Joc. "I am enthused to partner with ISBG and look forward to a bright future with ISBG."
As part of each five-year contract, ISBG will provide and approve brand marketing support in several areas including artist production, artist video, concert production, endorsement by the artists, after parties for artists, music and song integration, product advertising, and branding for point of sale and point of purchase.
"We welcome Shad Moss and Yung Joc aboard the ISBG team. As fellow shareholders we look forward to a prosperous future," stated Jeff Freiberger, ISBG's Chief Operating Officer. "This arrangement is a testament to our celebrities' confidence in the future of ISBG. We look forward to updating shareholders with more detailed information in the near future."
About (ISBG) International Spirit & Beverage Group, Inc:
ISBG, based in Houston, TX, is an alcoholic beverage company specializing in the development, global sales, and marketing of innovative wine & spirits brands. The Company's expertise lies in the strategic development and aggressive early growth of its brands establishing its assets as viable and attractive acquisition candidates for the major global spirits companies. ISBG intends to build its brands as individual acquisition candidates while continuing to develop its pipeline of new brands in to the ISBG portfolio. ISBG's existing portfolio contains three brands: Cavoda Vodka (www.cavodavodka.com), Besado Tequila (www.besadotequila.com) and Dziaq Liqueur (www.dziaq.com).
For more information visit: www.isbg.global
Link back to International Spirit & Beverage Group, Inc. on NuziNet.com
Contact:
International Spirit & Beverage Group, Inc.
info@isbg.global
Follow on Twitter https://twitter.com/DrinkISBG
BETS in at .0019. I hear there are many PRs about to hit the runway!
$PMCB Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, said that his company's recent decision to partner with a privately held San Diego biotech was to "hedge our bets to make sure we would win in this space." Johnson & Johnson's deal with ViaCyte, Inc. is an effort to speed up the development of ViaCyte's stem cell treatment for Type 1 diabetes. Winning in the diabetes space, however, might mean that Johnson & Johnson or another larger company in the biopharmaceutical industry will need to take a long look at PharmaCyte Biotech (OTCQB: PMCB), a small Silver Spring, Maryland firm with its own Type 1 diabetes treatment.
After sitting in on PharmaCyte's second annual International Diabetes Consortium meeting in Vienna, Austria, it was clear that PharmaCyte has a treatment that many other companies, organizations and research institutes have yet to prove they're capable of producing. It is this treatment that Johnson & Johnson and other biopharmaceutical companies should be eyeing very closely. In order to pull off the feat of developing a successful treatment or "cure" for those who are insulin dependent, most researchers are looking for three key ingredients. And PharmaCyte has all three: (1) a cell line capable of producing insulin that can act as an "artificial pancreas," (2) an encapsulation technology that can house the cell line inside the body and keep it protected from the body's immune system, and finally (3) a team of experts in the diabetes arena that can bring the treatment to life.
PharmaCyte's treatment for type 1 diabetes and type 2 insulin-dependent diabetes is an encapsulated human cell line, called the Melligen cell line, which are liver cells that have been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. PharmaCyte will encapsulate the Melligen cells using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Developing a successful diabetes treatment for Type 1 diabetics all starts with a cell line that is capable of producing insulin on demand. Unlike most who have turned to islet cells or stem cells, PharmaCyte has instead turned to Professor Ann Simpson, one of the 17 members on PharmaCyte's international diabetes consortium, and her colleagues at the University of Technology-Sydney in Australia. Professor Simpson and her team conducted numerous tests during the various stages of the development process and studies were carried out to show that Melligen cells secreted insulin in response to physiological concentrations of glucose (blood sugar). Furthermore, when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal. This observation illustrates that Melligen cells can reverse the diabetic condition.
Their work was published in a major research article titled "Reversal of diabetes following transplantation of an insulin-secreting human liver cell line: Melligen cells" in the journal Molecular Therapy - Methods & Clinical Development: http://www.nature.com/articles/mtm201511
The authors of the article note that, for the Melligen cells to be effective in treating Type 1 diabetes in humans where the insulin-producing beta cells of the pancreas have been destroyed, it will be necessary to protect these cells from rejection by the body's immune system after they have been introduced into the body. The article points out that one way to protect the Melligen cells would be to encapsulate the cells in protective "cocoons" prior to being placed into a diabetic patient. If this is done, the authors believe that encapsulated Melligen cells may offer a cure for Type 1 diabetes.
Enter step 2 of PharmaCyte Biotech's three-pronged approach, an encapsulation technology capable of protecting the genetically engineered live cells inside. The ability to encapsulate a cell line and keep it protected from immune system attack to treat diabetes has been called the "holy grail" of cell encapsulation. PharmaCyte's live-cell encapsulation technology, Cell-in-a-Box®, appears to be the ideal encapsulation technology for this purpose. In fact, Melligen cells have already been successfully encapsulated using the Cell-in-a-Box® process, and the first preclinical studies have shown that Melligen cells are equally as safe inside the Cell-in-a-Box® capsules as the encapsulated cells that PharmaCyte will be using in its upcoming FDA human clinical trials in advanced pancreatic cancer.
So, with the Melligen cell line in place, and with Cell-in-a-Box® set to house the cell line to keep it protected, the final piece to developing a successful treatment for Type 1 diabetes is a team of experts who can put it all together, test it, modify the treatment where necessary, perfect the dosing in a number of animal models and get the treatment into clinical trials as quickly as possible.
PharmaCyte's CEO, Kenneth L. Waggoner, has assembled 17 experts in the field of diabetes from all over the globe. This group makes up PharmaCyte's International Diabetes Consortium. They have all come together to work toward one goal -- developing an "artificial pancreas" or a "cure" for insulin dependent diabetes. All of these experts are working at the same time in their specific area of expertise rather than waiting for each experiment to run its course before moving on to the next group of experts. It is this approach that should expedite PharmaCyte's path to human clinical trials. PharmaCyte's approach should provide answers more quickly for those larger biopharmaceuticals that expect to win the race to the first truly long-term successful type 1 diabetes treatment.
About Stock Market Media Group
Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.
Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at: www.sec.gov, where you can also find all of PMCB's filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.
We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.
For more information: www.stockmarketmediagroup.com.
LEAS ready to brk out
ASTI moving up today after a 3 day dip.
INKW: Check this one out folks! 4M float here! .009! Big box store chatter here!
$PMCB PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
Forecasts for the number of people that will be diagnosed with diabetes in the coming years are staggering. While many treatments exist to treat some of the effects of diabetes on patients afflicted with the disease, a “holy grail” to truly treat the disease has yet to be developed. Clearly, an out of the box approach is required. If future test results affirm the data derived from recent studies, the PharmaCyte Biotech (OTCQB – PMCB - $0.07 – Spec Buy) Cell-in-a-Box® diabetes treatment platform could emerge as the treatment of choice for this disease.
Dozens of studies and trials to treat Type 1 and Type 2 diabetes are ongoing, given that the size of the global diabetes market for therapeutic devices and drugs is expected to reach US $114.3 billion by 2018, according to a report by Transparency Market Research. However, since results have been mixed for even the largest and most successful companies, industry participants are now exploring new ideas and new approaches that have demonstrated efficacy in early studies, which could serve as an indirect or direct benefit to PharmaCyte.
For example, one of the top two players in diabetes treatment, Novo Nordisk (NYSE – NVO), announced that it is collaborating with IBM (NYSE – IBM) to combine IBM’s cognitive computing capabilities with diabetes research by collecting and analyzing real-time data from patients using Novo Nordisk treatments and devices. The hope is that this venture leads to improved solutions for diabetes management. Novo Nordisk also submitted a new type of fast-acting mealtime insulin to the FDA for approval, a departure from its primary offerings. Meanwhile, Novo Nordisk competitor Eli Lilly (NYSE – LLY), which has had six diabetes treatments approved since 2014 halted development of a promising diabetes treatment under development. If a company with 6 approved drugs in a treatment category is still working on the problem, and another leader is moving outside of its comfort zone in an effort to develop the most effective therapy available, it is an indication that the time is now for PharmaCyte.
The Company has the exclusive worldwide rights to use Melligen cells to treat diabetes. Melligen cells are genetically engineered from human liver cells and have been shown to secrete insulin in response to the concentrations of glucose (blood sugar) in their environment. A recent article published in scientific journal Molecular Therapy noted that when Melligen cells were transplanted into diabetic mice whose immune systems were essentially not functioning, the blood glucose levels of the mice became normal.
This observation illustrates that Melligen cells can reverse the diabetic condition. PharmaCyte plans to encapsulate a human cell line that has been genetically modified to produce, store and release insulin in response to blood glucose levels in their surroundings. Therefore, the Melligen cell line, when combined with Cell-in-a-Box® encapsulation, could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes and Type 2 insulin-dependent diabetes and could potentially replace them. As a result, we look for these shares to move toward the $0.20 level in early 2016.
CGRA up 33%. Break .0032 it runs hard. Slam the ask. County approval on the 17th
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
Refer to all of Space's posts. They accurately advise the current state of TDEY. It's not Manipulation. It's not shorting. It's not wanting cheap shares.
It's calling a scam, a scam
$tdey imo
I got out in the .0004-5 corridor when FINRA was a no show... Kent gone? Explain..
News out, NGEY
THERMAL, Calif., March 10, 2016 /PRNewswire/ -- New Global Energy, Inc. (OTCQB: NGEY) ("the Company"), a public company focused on Aqua-Farming, Agriculture, and Health & Wellness, announced today that its tilapia season is in full swing and on schedule to produce record breaking revenue.
http://photos.prnewswire.com/prnvar/20160310/342886
At Aqua Farming Tech, NGE's wholly owned subsidiary, there are two spawning seasons in the Spring and Fall that produce one million tilapia each that we expect to be a total of two million annually. This month, the Fall season's tilapia are coming to full maturity at approximately one pound each and are preparing to go to market at $3.60 per pound (delivered) or $3.00 per pound (picked up at the farm) with price increases expected.
"We are very pleased that our tilapia farm operation in the Coachella Valley is more profitable and sustainable than ever before," said Chief Executive Officer Perry D. West. "As soon as our tilapia reach full market size we are ready to ramp up sales in order to meet increased consumer demand for quality seafood. 2016 will be a record year for our farms."
New Global Energy's farms are uniquely suited to grow tilapia, which is a tropical fish, because of the area's warm climate and the availability of warm fresh water from geo-thermally heated wells. The company's proprietary fish feeding methodology saves up to 70% on overall feed costs. The fish are fed nutrient rich algae and other aquatic plants for their first four months in grow-out ponds that represent a natural environment.
About New Global Energy, Inc.
New Global Energy, Inc. (www.newglobalenergy.net) is a public company focused on acquiring high-growth firms, assets and properties in the Aqua-Farming, Agriculture, and Health & Wellness industries. The trading symbol is NGEY traded on the OTCQB. New Global Energy seeks to create sustainable projects and protect the environment.
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
For more information please contact:
Charlotte Luer, Director of Investor Relations
cluer@newglobalenergy.net
+1-239-404-6785
Photo - http://photos.prnewswire.com/prnh/20160310/342886
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tilapia-production-fully-underway-at-new-global-energy-inc-300234170.html
SOURCE New Global Energy, Inc.
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
Followers
|
48
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
933
|
Created
|
12/31/15
|
Type
|
Premium
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |